Clinical diagnostics group Novacyt’s exsig Covid-19 Direct Real-Time PCR test has received approval from the UK’s Health Security Agency.
Novacyt said on Friday that the exsig Covid-19 test was designed to detect a SARS-CoV-2 gene target within ORF1ab and, as with all of its direct-to-PCR products, removes the need for manual or automated extraction solutions to “significantly improve” laboratory workflow and reduce costs.
In addition to this, Novacyt said the test was designed for use on an open platform, meaning it can be used with the company’s q16 and q32 instruments, as well as other validated systems.
Chief executive David Almond said: “To ensure Novacyt is well positioned for any future COVID-19 outbreaks, the company continues to consolidate its portfolio. The approval of exsig Covid-19 Direct supports this aim, complementing the company’s existing PCR portfolio for Covid-19 testing in the UK and further reinforcing Novacyt’s position as a first responder in infectious diseases.”
As of 1015 BST, Novacyt shares were up 8.67% at 117.15p.
Reporting by Iain Gilbert at Sharecast.com